Daily Cosmetic Research Analysis
Analyzed 44 papers and selected 3 impactful papers.
Summary
Three impactful studies span cosmetic safety, innovation, and procedural precision: a new near-infrared probe quantifies hypochlorous acid to visualize keloid activity and treatment response; a global meta-analysis defines the real-world burden of contact allergy to formaldehyde and its releasers, informing regulation and patch testing; and a prospective, ultrasound-guided 11-point lip injection protocol demonstrates safe, reproducible aesthetic outcomes with no major complications.
Research Themes
- Imaging biomarkers for fibrotic skin disorders
- Cosmetic ingredient safety and regulation
- Ultrasound-guided precision aesthetic procedures
Selected Articles
1. Engineering an Activatable Near-Infrared Fluorogenic Probe for Hypochlorous Acid in Keloid Diagnosis and Therapeutic Evaluation.
This translational study introduces DQFCl-HOCl, an activatable NIR probe that sensitively and selectively images hypochlorous acid in keloid fibroblasts and patient-derived xenografts. HOCl signals are elevated in keloid fibroblasts and decrease with RepSox or triamcinolone, enabling dynamic monitoring of therapeutic response and linking redox pathways to TGF-β–driven fibrosis.
Impact: Provides a mechanistic, imageable biomarker for keloid activity and treatment response, addressing a major unmet need for objective disease monitoring in fibrotic skin disorders.
Clinical Implications: While preclinical, the probe could enable noninvasive stratification of active keloid lesions and real-time assessment of intralesional corticosteroid efficacy, informing personalized dosing and trial endpoints.
Key Findings
- Engineered an activatable NIR fluorogenic probe (DQFCl-HOCl) with rapid response, nanomolar sensitivity, and high selectivity for hypochlorous acid.
- Keloid fibroblasts exhibited markedly higher HOCl fluorescence than normal dermal fibroblasts; signals decreased after RepSox or triamcinolone acetonide.
- In a patient-derived xenograft model, the probe distinguished keloid tissue and dynamically visualized therapeutic response to corticosteroid.
- Transcriptomics and Western blot linked redox regulation pathways to TGF-β–centered fibrotic signaling.
Methodological Strengths
- Multimodal validation across cell models and patient-derived xenografts.
- Quantitative transcriptomics integrated with protein validation to support mechanistic pathways.
Limitations
- Preclinical study without human in vivo imaging or clinical outcomes.
- Safety, biodistribution, and specificity in human skin remain to be established.
Future Directions: Translate to first-in-human imaging to correlate HOCl signals with clinical activity and histopathology, and evaluate as a pharmacodynamic biomarker in interventional trials.
Keloid is a skin fibrosis disease characterized by continuous deposition of extracellular matrix and invasive expansion of the lesion. Hypochlorous acid (HOCl), an important member of the reactive oxygen family, has been proven to participate in the activation process of fibroblasts in various fibrosis diseases. However, the dynamic changes in keloid have not been fully explored. Herein, we constructed an activatable near-infrared fluorogenic (NIRF) probe DQFCl-HOCl for visualizing HOCl and exploring its association with the pathological activity of keloid. DQFCl-HOCl featured NIRF emission, rapid response, nanomolar-level detection sensitivity, and excellent selectivity. In cell models, DQFCl-HOCl could image exogenous and endogenous HOCl. More importantly, the HOCl fluorescence signal in keloid fibroblasts was markedly higher than that in normal dermal fibroblasts, and it decreased after intervention with RepSox or triamcinolone acetonide (TA). In a patient-derived xenograft model, DQFCl-HOCl could distinguish keloid tissue in mice and dynamically visualize the therapeutic effect of TA. Additionally, transcriptomic coexpression network analysis combined with Western blot results indicated that redox regulation pathways were closely coupled with the fibrotic signaling network centered on TGF-β. This work provided a new chemical imaging tool for tracing the redox microenvironment of keloid and evaluating therapeutic response.
2. The Prevalence of Contact Allergy to Formaldehyde and Formaldehyde Releasers: A Systematic Review and Meta-Analysis.
Pooling 158 studies (1.35 million dermatitis patients), this meta-analysis estimates a 2.88% prevalence of formaldehyde contact allergy with 41.6% clinical relevance and quantifies sensitization to key releasers. Marked regional differences, particularly higher prevalence in North America, and high clinical relevance of quaternium-15 underscore the impact of regulatory bans and inform patch testing and product formulation.
Impact: Defines the global burden and clinical relevance of formaldehyde-related allergy at unprecedented scale, directly informing regulatory policy, clinical patch testing panels, and cosmetic preservative choices.
Clinical Implications: Supports avoidance strategies and regulatory restrictions for high-relevance releasers (e.g., quaternium-15), guides inclusion of allergens in baseline patch test series, and aids counseling across age groups and atopic status.
Key Findings
- Pooled prevalence of formaldehyde allergy among dermatitis patients: 2.88% (95% CI 2.55–3.24); clinical relevance 41.57%.
- Releaser prevalence: bronopol 2.76%, quaternium-15 1.89% (highest clinical relevance 55.67%), diazolidinyl urea 1.42%, DMDM hydantoin 1.37%, imidazolidinyl urea 1.20%.
- Highest regional prevalence in North America (6.8%); similar rates across children (2.96%) and adults (2.61%), and across AD (2.65%) vs non-AD (2.85%).
Methodological Strengths
- Very large aggregated sample (1,347,638 patients) with random-effects meta-analysis.
- Subgroup analyses by geography, age, and atopic status enhance external validity.
Limitations
- Heterogeneity in patch test protocols and concentrations across studies.
- Clinic-based dermatitis populations may overestimate general population prevalence; potential publication bias.
Future Directions: Harmonize patch testing methods globally, monitor temporal trends post-regulation, and expand surveillance to community-based cohorts to refine risk estimates.
Formaldehyde and its releasers are common preservatives and potent sensitizers. This meta-analysis aimed to estimate the prevalence of formaldehyde contact allergy and allergy to its five most common releasers among dermatitis patients. Two authors independently searched PubMed, Embase, and Web of Science from inception to 30th September 2025. A proportion meta-analysis was conducted using a random-effects model. A total of 158 studies involving 1 347 638 dermatitis patients were included. The pooled prevalence of formaldehyde contact allergy was 2.88% (95% CI 2.55-3.24) with clinical relevance at 41.57%. The pooled prevalence for releasers was 2.76% for 2-bromo-2-nitropropane-1,3-diol, 1.89% for quaternium-15, 1.42% for diazolidinyl urea, 1.37% for DMDM hydantoin, and 1.20% for imidazolidinyl urea. Quaternium-15 showed the highest clinical relevance at 55.67%. Significant sensitization rates were observed in different geographic regions, with the highest prevalence found in North America (6.8%). The prevalence rate was 2.96% among children and 2.61% among adults, with no significant difference. The prevalence rate was 2.65% among patients with atopic dermatitis (AD) and 2.85% among patients without AD, with no significant difference. The profound geographic disparities suggest that regulatory interventions, such as the EU's prohibition of formaldehyde and quaternium-15 in cosmetics, are highly effective public health measures.
3. Enhancing Lip Augmentation Safety and Aesthetics Through 11-Point Injection Technique and Sonographic Vascular Mapping.
In a prospective cohort of 25 women, pre-injection ultrasound mapping of labial arteries combined with an 11-point injection protocol produced favorable aesthetic outcomes and no major complications. Quantitative 3D and sonographic measures documented arterial depth, volume trajectories, lip thickness changes, and sustained GAIS scores over 6 months.
Impact: Introduces a practical, image-guided protocol that directly mitigates vascular risk in a high-volume cosmetic procedure while providing reproducible, quantifiable outcomes.
Clinical Implications: Adoption of pre-injection sonographic vascular mapping with structured 11-point injections may reduce intravascular injection risk, guide depth/plane selection, and support objective follow-up using 3D metrics.
Key Findings
- Mean midline arterial depth: upper lip 2.54 ± 1.89 mm; lower lip 1.91 ± 1.58 mm, increasing laterally.
- Immediate post-injection lip volume increase (0.96 ± 0.24 mL) declined to 0.58 ± 0.17 mL at 6 months.
- Upper lip thickness rose from 8.94 ± 1.16 to 10.98 ± 1.03 mm at 1 month; lip corner elevation averaged 1.21 ± 0.35 mm.
- Global Aesthetic Improvement Scale remained favorable at 6 months (3.28 ± 0.75); no major complications observed.
Methodological Strengths
- Prospective design with standardized high-frequency ultrasound mapping and 3D imaging.
- Quantitative vascular depth measurements informing safe injection planes.
Limitations
- Single-center, small sample size (n=25), all female; no control group.
- Use of a single filler product limits generalizability; follow-up limited to 6 months.
Future Directions: Randomized comparative studies versus standard techniques, inclusion of diverse fillers and patient demographics, and evaluation of complication reduction at scale.
BACKGROUND: Lip augmentation using hyaluronic acid fillers is a popular cosmetic procedure; however, vascular complications remain a concern. The 11-point injection technique (11-PIT), combined with sonographic vascular mapping, enhances safety by guiding precise filler placement while achieving optimal aesthetic outcomes. METHODS: A prospective study was conducted on 25 female patients (21-65 y) undergoing lip augmentation with Cleviel Volume hyaluronic acid filler. High-frequency ultrasound (Aplio-i700, Canon Medical Systems) was used to measure the depth of superior and inferior labial arteries at 6 key points before injection. The 11-PIT was performed to enhance specific lip landmarks while minimizing vascular risks. Postprocedure assessments included 3-dimensional imaging for volume changes, sonographic analysis for lip thickness and projection, and Global Aesthetic Improvement Scale surveys at 1, 3, and 6 months. RESULTS: The mean arterial depth at the midline of the upper and lower lips was 2.54 ± 1.89 and 1.91 ± 1.58 mm, respectively, increasing laterally. Lip volume increased immediately postinjection (0.96 ± 0.24 mL) and gradually declined to 0.58 ± 0.17 mL at 6 months. Upper lip thickness increased from 8.94 ± 1.16 to 10.98 ± 1.03 mm at 1 month before regressing. Lip corner elevation was measured at 1.21 ± 0.35 mm at 1 month. Global Aesthetic Improvement Scale scores remained favorable (3.28 ± 0.75 at 6 mo). No major complications occurred. CONCLUSIONS: The 11-PIT, combined with sonographic vascular mapping, provides a safe and effective approach for lip augmentation. This method minimizes vascular risks, enhances aesthetic outcomes, and offers reproducible results, supporting its adoption for safer lip enhancement procedures.